Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Karsten Munk Knudsen, CFO of Novo Nordisk, discusses the prospect of tariffs on pharmaceuticals and the importance of the U.S ...

Healthcare stocks led sectoral decliners in Europe on Wednesday, as President Donald Trump's latest threat of higher tariffs ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...

Super Micro, AMD, and Snap stocks tumbled after quarterly earnings reports. Arista and Disney stocks were rising.

President Trump’s latest tariff threat has targeted a sector that’s already hobbled.